Fish Oils (Omega 3) in ischaemic stroke

INTERVENTION: Participants receive 3 gm of fish oil (containing omega‐3 PUFAs) orally for the treatment group Participants are seen at 0 and 12 weeks for clinical assessments, anthropometry, venepuncture for haematological and biochemical analyses, assessment of compliance and the recording of adverse events. In addition, a telephone follow‐up visit will be performed at 6 and 11 weeks to ascertain safety data (SAEs) and compliance to study treatment. CONDITION: Ischaemic Cerebrovascular Disease Ischaemic Cerebrovascular Stroke PRIMARY OUTCOME: To evaluate the effectiveness of Omega‐3 PUFAs in improving lipid profiles SECONDARY OUTCOME: Lipid profile (TC, LDL‐C, HDL‐C, TG [primary]; LDL‐particle size, Apo B), inflammatory markers (hsC‐RP, LFT, FBC, ESR, ferritin), haemostatic clotting (fibrinogen), blood pressure, body mass index (BMI), body weight, waist to hip ratio, mood (GHQ 28‐item general health questionnaire) and health‐related quality of life (SF‐36 item short form questionnaire). To evaluate the treatment on changes in weight, blood pressure, inflammatory and haemostatic markers of cardiovascular disease, and mood. INCLUSION CRITERIA: 1. CT confirmed first‐ever or recurrent ischaemic stroke 2. Clinically stable with atheromatous disease history greater than 3 months.